Recruiting
Phase 3

APC-0101

Sponsor:

Aerogen Pharma Limited

Code:

NCT06776783

Conditions

Respiratory Distress Syndrome

Pre-term Infants

Eligibility Criteria

Sex: All

Age: 0

Healthy Volunteers: Not accepted

Interventions

APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system)

Control

Study Details

Brief summary:

This is a 2-part, prospective, randomized, blinded, sham-controlled, multi-center study comparing preterm subjects with RDS who are treated with APC-0101 and nCPAP/NIV to subjects treated with nCPAP/NIV alone (Sham). In Part 1, subjects will be followed until they reach 40 weeks post-menstrual age (PMA) or are discharged from the NICU, whichever comes first. In Part 2, subjects will undergo post-term follow-up through 24 months corrected age.

Conditions

Respiratory Distress Syndrome

Pre-term Infants

Study ID

NCT06776783

Start date

Sep 24, 2025

Status verified date

Aug, 2026

Completion date

May, 2029

Anticipated

Primary completion date

May, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Inborn at the study site's hospital (i.e., not transferred from another hospital following delivery)
2. Gestational age at birth of 26 through 33 weeks PMA
3. Birth weight appropriate for gestational age (AGA, weight 3rd to 97th percentile on Fenton Growth Curve)
4. Birth weight ≤ 2000 grams
5. Post-natal age 1 to 24 hours at randomization
6. On nCPAP or NIV for at least 30 minutes with RSS = 1.4 - 2.0 to maintain SpO2 90-95% at randomization. RSS is calculated as (nCPAP cm H2O) × (FiO2) or as (NIV mean airway pressure cm H2O) × (FiO2).
7. FiO2 ≥ 0.24 at randomization
8. nCPAP or mPaw ≥ 6 cm H2O at randomization
9. Chest radiograph (CXR) or lung ultrasound compatible with RDS prior to randomization

Exclusion Criteria:

1. On SiPAP®, RAM® cannula, or high flow nasal cannula (HFNC) (> 2 liters per minute \[LPM\]) at the time of randomization
2. Prior instillation of surfactant
3. Premature rupture of membranes (PROM) occurring > 14 days before birth
4. Significant congenital/chromosomal anomaly (e.g., Pierre Robin syndrome, clinically significant congenital heart disease, or trisomy)
5. Pneumothorax
6. Other etiologies of respiratory distress
7. Enrollment in another interventional study with similar efficacy endpoints
8. Apgar score at 5 min of 0-3
9. Prior cardiopulmonary resuscitation (CPR) or epinephrine
10. Base Deficit > 15 mEq/L on most recent arterial blood gas (not capillary blood gas, venous blood gas, or cord gas) prior to randomization. Note that arterial blood gas is not required prior to randomization.
11. Partial pressure of carbon dioxide (PaCO2) > 65 mmHg on most recent arterial blood gas (not capillary blood gas, venous blood gas, or cord gas) prior to randomization.
12. Triplet or higher order multiple birth

Study Design

Enrollment

520 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

sham comparator: Control Group

experimental: APC-0101 Group

Interventions

APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system)

Subjects in the APC-0101 group will be changed from their current nCPAP/NIV interface to the APC-0101 nCPAP/NIV interface and APC-0101 treatment will be started.

Control

Subjects in the Control group will be changed from their current nCPAP/NIV interface to the APC-0101 nCPAP/NIV interface but an empty vial will be used instead of APC-0101.

Primary outcome measure

  • Failure Criteria [ Time Frame: First 7 days of life ]

Central Contacts and Locations

Central contacts

Locations

University of Arkansas for Medical Sciences

Recruiting

Little Rock, Arkansas, United States, 72205

Contacts

Jacobs Medical Center

Recruiting

La Jolla, California, United States, 92037

Contacts

UF Health Jacksonville

Recruiting

Jacksonville, Florida, United States, 32209

Contacts

Advent Health

Recruiting

Orlando, Florida, United States, 32803

Contacts

Memorial Hospital of South Bend

Recruiting

South Bend, Indiana, United States, 46601

Contacts

Goryeb Children's Hospital

Recruiting

Morristown, New Jersey, United States, 07960

Contacts

The Trustees of Columbia University in the City of New York

Recruiting

New York, New York, United States, 10032

Contacts

Montefiore Medical Center

Recruiting

The Bronx, New York, United States, 10461

Contacts

Maria Farreri Children's Hospital

Recruiting

Valhalla, New York, United States, 10595

Contacts

Christus Children's Hospital

Recruiting

San Antonio, Texas, United States, 78207

Contacts

University of Virginia School of Medicine

Recruiting

Charlottesville, Virginia, United States, 22903

Contacts

Heeju Snyder, CCRP

hvw8cy@uvahealth.org

WVU Medicine Children's Hospital

Recruiting

Morgantown, West Virginia, United States, 26506

Contacts

More Information

Sponsor

Aerogen Pharma Limited

Last update posted

Aug 6, 2026

Last verified

Aug, 2026

Keywords

  • respiratory distress syndrome
  • surfactant
  • pre-term infant

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Aerogen Pharma Limited on 2026-08-06.